Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
26,582 people get JNJ articles and Market Currents by email alert.
Get email alerts on JNJ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Johnson & Johnson's CEO Hosts Annual Meeting of Shareholders (Transcript)Thu, Apr 26, 2012 • 1 Comment
-
Johnson & Johnson Services, Inc. Q2 2010 Earnings Call TranscriptTue, Jul 20, 2010
-
Johnson & Johnson Q1 2010 Earnings Call TranscriptTue, Apr 20, 2010
-
Johnson & Johnson Q4 2009 Earnings Call TranscriptTue, Jan 26, 2010
-
Johnson & Johnson Q3 2009 Earnings Call TranscriptTue, Oct 13, 2009
-
Johnson & Johnson Q2 2009 Earnings Call TranscriptTue, Jul 14, 2009
-
Johnson & Johnson F1Q09 (Qtr End 03/29/09) Earnings Call TranscriptTue, Apr 14, 2009 • 1 Comment
-
Johnson & Johnson Q4 2008 Earnings Call TranscriptTue, Jan 20, 2009
-
at CNBC.com (Wed, 1:16PM)
-
at CNBC.com (Mon, 6:00PM)
-
at CNBC.com (May 17, 2013)
-
at CNBC.com (May 17, 2013)
-
at MarketWatch.com (May 17, 2013)
-
at CNBC.com (May 14, 2013)
-
at MarketWatch.com (May 14, 2013)
-
at MarketWatch.com (May 12, 2013)
-
at MarketWatch.com (May 3, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Apr 25, 2013)
-
PR Newswire (Apr 25, 2013)
-
PR Newswire (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
JNJ vs. ETF Alternatives
Company Description
General
Johnson & Johnson and its subsidiaries have approximately 115,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 250 operating... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, April 4, 4:25 PM Johnson and Johnson (JNJ) subsidiary Cordis Corp notches a legal victory as the U.S. Court of Appeals for the Federal Circuit overturns a ruling ordering a payment of $482M to radiologist Bruce Saffran. Saffran alleges patent infringement in connection with Cordis' Cypher stents. Comment! [Healthcare]
- Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]
- Wednesday, April 3, 11:51 AM Astex Pharmaceuticals (ASTX +12.5%) gets a pop from RBC today, who initiated coverage with an Outperform and a $9 price target, calling it an "undiscovered gem." The firm says the ASTX could have a blockbuster in its pipeline with its experimental blood cancer drug, SGI-110, which is thought to be a safer and more effective version of an already approved therapy it licenses to Eisai (ESALY.PK) and JNJ. ASTX owns all the rights to SGI-110, giving it big upside potential if it gets approved. Additionally, the company reported earlier that it plans to present "significant data" at the AACR annual meeting on Saturday. Comment! [Healthcare, On the Move]
- Monday, April 1, 9:09 AM Medical products maker Covidien (COV) says it was awarded $176M as a federal court ruled several patents were infringed by Johnson & Johnson's (JNJ) Ethicon Endo-Surgery unit and its Harmonic line of ultrasonic surgical products. Comment! [Healthcare]
- Sunday, March 31, 4:14 AM The FDA has approved J&J's (JNJ) Invokana drug for treating type 2 diabetes in a new way by causing the body to excrete blood sugar via the urine rather than affecting the supply or use of insulin. The agency said J&J must carry out five post-marketing studies to determine whether the drug increases the risks of strokes, heart attacks and other side effects. Invokana is forecast to generate sales of $667M by 2016. 5 Comments [Healthcare]
- Wednesday, March 27, 3:08 PM Amgen (AMGN +1%) and Johnson & Johnson (JNJ +0.5%) also hit new 52-week highs today on the back of developments stemming from Kinmed and PFE's non-exclusive partnership. Comment! [Healthcare]
- Tuesday, March 26, 3:32 PM Shares of Johnson & Johnson (JNJ +1.5%) are trading at a fresh all-time high today, ratcheting up an ongoing a streak of higher highs since the beginning of the year after UBS ups its price target on the shares from $81.00 to $87.00. If the stock closes out the week above $79.74, this could be it's longest winning streak in at least 20 years. 6 Comments [Healthcare, On the Move]
- Monday, March 11, 8:56 AM Having been on the wrong end of an $8.3M award over its recalled all-metal ASR hip implants on Friday in LA, J&J (JNJ) is due in a Chicago court today for the start of another trial over the device. Illinois nurse Carol Strum contends that the ASR was defective and that the company didn't warn her of the risks. Overall, J&J faces 10,750 lawsuits related to the implant. 1 Comment [Healthcare]
- Sunday, March 10, 5:00 AM With companies looking to avoid paying taxes on their profits, 83 of the largest firms kept $1.46T overseas in 2012, up 14.4% from the previous year, Bloomberg calculates. GE (GE) again had the most with $108B held offshore, up from $102B in 2011; Pfizer was second with $73B, after which came Microsoft (MSFT), Merck (MRK), Johnson & Johnson (JNJ) and IBM (IBM). 73 Comments [U.S. Economy, Healthcare, Tech, Consumer, Financials]
- Friday, March 8, 4:05 PM A court jury in Los Angeles has awarded $8.3M in damages to a man who said he was injured by Johnson & Johnson's (JNJ +0.5%) all-metal hip implants, which the jury found were designed defectively. The verdict ends the first trial of about 10,750 product-liability lawsuits filed against JNJ's DePuy unit, which manufactured the ASR XL hip- replacement devices. 6 Comments [Healthcare]
- Wednesday, March 6, 8:51 AM SA Author Amit Cohen of Biomed Group delves into the strong initial sales of Medivation's (MDVN) Xtandi treatment for prostate cancer, which was launched in the U.S. in September. Q4 revenues of the drug were $57.4M, while those of J&J's (JNJ) rival product Zytiga fell 16% sequentially. Although Xtandi is more expensive, it has a "number of advantages" over Zytiga. Comment! [Healthcare, Quick Ideas]
- Tuesday, March 5, 8:27 AM The FDA has again rejected expanding the use of J&J's (JNJ) Xarelto blood thinner to patients with acute coronary syndrome, confirming a decision it made in June. The agency is concerned that the drug, which J&J co-markets with Bayer, could cause life-threatening bleeding. However, J&J unit Janssen says that "while we saw an increase in major bleeding, there was no increase in fatal bleeding." Comment! [Healthcare]
- Monday, March 4, 3:15 PM A combination of Gilead's (GILD +0.6%) Sofosbuvir and Simeprevir, a drug being jointly developed by Medivir (MVRBF.PK) and Johnson & Johnson's (JNJ) Janssen unit, eliminates hepatitis C in all 80 patients in a Phase IIa study. The patients had failed to respond to other treatments. "We went for the most difficult to cure, with the idea if we could show good efficacy there, it could be assumed the regimen could be efficacious in other patient populations," says Gaston Picchio of Medivir partner J&J (JNJ +0.5%). (PR) 2 Comments [Healthcare]
- Monday, March 4, 9:50 AM Shares in GSK (GSK -0.6%), Pfizer (PFE +0.3%) and Abbott (ABT +0.2%) show little reaction to news that lamivudine and zidovudine, which they sell in a JV, helped cure a 2/12 year old infant of HIV. Other firms that develop HIV treatments, including Merck (MRK +0.4%), J&J (JNJ +0.35%) and Gilead (GILD +0.3%), also don't seem too impressed. Comment! [Healthcare]
- Tuesday, February 26, 10:03 AM The award of $3.35M against J&J (JNJ +0.8%) over its vaginal mesh in a case involving a South Dakota patient could have an impact on other suits against the company and rival manufacturers C.R. Bard (BCR +0.3%), Boston Scientific (BSX -0.3%) and Endo Health (ENDP +0.3%). Around 11,000 claims have been consolidated into five cases that are pending in West Virginia. Comment! [Healthcare]
- Tuesday, February 26, 3:19 AM A jury is due to start hearing arguments today about the punitive damages that Johnson & Johnson (JNJ) should pay for harm caused to a South Dakota patient by the company's Gynecare Prolift vaginal mesh. The jury yesterday ordered the company to pay Linda Gross $3.35M in an initial award. J&J faces 4,000 lawsuits over the product in the U.S., although Morningstar analyst Damien Conover reckons the firm should be able to withstand any further penalties. Comment! [Healthcare, Top Stories]
-
- View all 0 replies
-
Dividend Sheet
$SDR $MEMP and $BBEP are the best yielding stocks with recent dividend hikes - http://stks.co/jT59 - 89 shares with 4.02% Yield $JNJ $WFC - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Casey Hoerth
Big news of the day for dividend investors? $JNJ grew its revenues 8% YoY. This bodes very well for us... - View all 0 replies
-
- View all 0 replies
-
- View all 5 replies
-
-
bdy: yep I lost money but I think I made a decent assumption on the trade so I'm okay with the small loss
-
- View all 0 replies
-
- View all 7 replies
-
Ocean Man: If CAT dips next Monday into the 70s, that could be interesting. -
-
O. Young Kwon
TANER Stock Model (TSM) Momentum 4/11/2013 (Thursday): (1-2-3) Home Depot ($HD) Johnson & Johnson ($JNJ) Nu Skin ($NUS) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
LATEST REPLIES
-
O. Young Kwon
TANER Stock Model [TSM] Momentum 1/22/2013 (Tuesday): (1-2-3) Johnson & Johnson ($JNJ) Intuitive Surgical ($ISRG) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
O. Young Kwon
TANER Stock Model [TSM] Momentum 1/14/2013 (Monday): (1-2-3) Johnson & Johnson ($JNJ) Coca Cola ($KO) Joy Global ($JOY) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
O. Young Kwon
TANER Stock Model [TSM] Momentum 10/23/2012 (Wednesday): (3) Johnson & Johnson (JNJ) Nike (NKE) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
Regarded Solutions
these are the days where some of our "dry powder" can be used: GE, T, JNJ are all on sale. - View all 15 replies
-
-
-
hat_trick3
when you finally see laggards like GE and JNJ reach highs last week, you know the bell was just rung. - View all 1 replies
-
hat_trick3: I knew it. when the laggards rally, you know the rally is over. Get ready for several more big legs down.
-
Regarded Solutions
Looks like JNJ is recovering of course, but T still offers a buying opportunity. See me articles on both. - View all 3 replies
-
Regarded Solutions: bigger company more moola and a little better yield right now....plus, I already own it!
-
-
- View all 4 replies
-
O. Young Kwon: article: Link:http://seekingalpha.com/a/hitr The TANER System synthesizes performances and relative strengths thoroughly <c>
-
O. Young Kwon: The letters in the parentheses are ticker symbols which are in THE TANER DATA (my Instablog) with their security names. yk
-
Ashraf Eassa
Lightened up my exposure to $INTC. Still long, but now underweight relative to my solid performers: $JNJ, $AEP, $VZ. - View all 6 replies
-
westcoastinvests: yes every pop has been sold for weeks its been impressive, i only exit INTC with stops worth a few pennies for a more open ended gain -
-
- View all 3 replies
-
O. Young Kwon: article: Link:http://seekingalpha.com/a/hitr The TANER System synthesizes performances and relative strengths thoroughly <c>
-
O. Young Kwon: The letters in the parentheses are ticker symbols which are in THE TANER DATA (my Instablog) with their security names. yk
-
- View all 3 replies
-
O. Young Kwon: article: Link:http://seekingalpha.com/a/hitr The TANER System synthesizes performances and relative strengths thoroughly <c>
-
O. Young Kwon: The letters in the parentheses are ticker symbols which are in THE TANER DATA (my Instablog) with their security names. yk
-
O. Young Kwon
TANER Stock Model [TSM] Momentum 10/8/2012 (Monday): (1-2-3) Johnson & Johnson (JNJ) yk - View all 1 replies
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
- View all 3 replies
-
O. Young Kwon: article: Link:http://seekingalpha.com/a/hitr The TANER System synthesizes performances and relative strengths thoroughly <c>
-
O. Young Kwon: The letters in the parentheses are ticker symbols which are in THE TANER DATA (my Instablog) with their security names. yk
-
- View all 3 replies
-
O. Young Kwon: article: Link:http://seekingalpha.com/a/hitr The TANER System synthesizes performances and relative strengths thoroughly <c>
-
O. Young Kwon: The letters in the parentheses are ticker symbols which are in THE TANER DATA (my Instablog) with their security names. yk